The TKIs shown are known or predicted to be active against rearrangements involving the listed kinase in experimental models, but with the exception of imatinib/dasatinib in EBF1-PDGFRB ALL, have not been shown to be effective in ALL. Several ABL1-class and JAK kinases are rearranged to multiple fusion partners. (Data are taken from Roberts et al.²⁰ )